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Introduction
Large-scale sequencing tests, including whole-exome and whole-genome sequencing (WES/
WGS), are rapidly moving into clinical use.1 Sequencing is already being used clinically to 
identify therapeutic opportunities for cancer patients who have run out of conventional 
treatment options, to help diagnose children with puzzling neurodevelopmental conditions, 
and to clarify appropriate drug choices and dosing in individuals. To evaluate and support 
clinical applications of these technologies, the National Human Genome Research Institute 
(NHGRI) and National Cancer Institute (NCI) have funded studies on clinical and research 
sequencing under the Clinical Sequencing Exploratory Research (CSER) program as well as 
studies on return of results (RoR). Most of these studies use sequencing in real-world 
clinical settings and collect data on both the application of sequencing and the impact of 
receiving genomic findings on study participants. They are occurring in the context of 
controversy over how to obtain consent for exome and genome sequencing,2 whether to 
return results, and the role of patient/ participant preferences — controversy fueled by 
publication of the American College of Medical Genetics and Genomics (ACMG) 
recommendations for clinical sequencing in 20123 and management of incidental findings in 
2013,4 with ensuing commentaries.5 Indeed, debate over the ACMG recommendations on 
incidental findings prompted a recent amendment of those recommendations.6
To identify approaches used at leading U.S. institutions engaged in translating sequencing 
from research to clinical care, we analyzed the consent forms used in six CSER studies 
(funded as of early 2012), and three R01 studies in the RoR (now CSER-ELSI) Consortium. 
All were written before the release of the 2013 ACMG recommendations on incidental 
findings,7 although some involve investigators who participated in that writing group. While 
prior work has analyzed consent forms in genome sequencing,8 these nine studies aim 
specifically to develop best practices for clinical use.9 By analyzing their consent forms, we 
sought to shed light on current approaches to consent for research on returning genomic 
results, broadly defined here to include both diagnostic and incidental findings from 
sequencing.10 In particular, we aimed to assess the degree to which broad areas of 
agreement were evident.
The nine studies are among the first NIH-funded studies to consider the many practical 
issues associated with clinical applications of WES/WGS. Each made relatively independent 
decisions about how to explain sequencing, its limitations, and potential findings. Our 
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analysis addresses four key questions: (1) What results do these studies plan to return to 
participants? (2) How are participant preferences taken into account in determining whether 
to return results? (3) What potential benefits and risks are identified? and (4) How are 
privacy, placement of results into the medical record, risk of re-identification, and data-
sharing addressed?
Methods
The authorship team for this article is drawn from the Informed Consent and Governance 
Working Group within the CSER-ELSI Consortium. All six studies funded by the CSER 
program as of early 2012 deposited at least one example of their current consent forms in a 
shared Consortium Internet site. We also identified three R01s studying return of 
WES/WGS results. We selected one consent form from each project for full analysis, either 
a form intended for adults undergoing sequencing or one intended for parents/ guardians 
giving permission for a child. For studies that used similar consent forms tailored to 
different disease conditions, we selected one. When studies included both adults and 
children, we selected the adult form. When individuals with and without identified disease 
conditions were included, we selected the form for affected individuals. These selection 
processes generated a total of nine forms for analysis.
To conduct a content analysis, four authors (PA, GH, SJ, and RS) developed a coding form 
based on initial review of all nine forms. Questions, codes, and quantitative and qualitative 
response categories were developed iteratively. Additional authors offered feedback and 
further modification. Development of the coding scheme benefited from the authors’ deep 
knowledge of the ethical and legal literature on consent to genetic and genomic research. 
The final coding sections included open and close-ended codes for: (1) description of study 
design and characteristics; (2) explanation of the sequencing test and its limitations; (3) 
categories of results to be returned (or not); (4) processes for return; (5) description of 
potential benefits and risks; (6) approaches to privacy, confidentiality, de-identification, re-
identification, and placing information in the medical record; (7) approaches to the use of 
specimens or data in other studies; and (8) other permissions sought. The coding form used 
is available on request.
Consent forms were then coded independently by two authors (GH and KK), followed by 
review and resolution of discrepancies. Quantitative data were entered into an Excel 
spreadsheet; qualitative text data were collected for each coding section. Both data types and 
the original consent forms were used in analysis, with teams of two authors assigned to 
produce section analyses which were subsequently reviewed by all authors.
Results
Study Characteristics
The nine studies involve heterogeneous populations, including adults and/or children with 
cancer, cardiovascular disease, intellectual disability/neurological conditions, and unaffected 
individuals. Five studies include comparison or control groups, introducing additional 
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diversity regarding the kinds of results offered, how, and to whom. There is also 
considerable variability in the length of the consent forms and reading level (see Table 1).
Study Purposes
The overall purpose of the studies is to understand the application of new sequencing 
technologies. WES is used in four studies, WGS in one, and both WES and WGS in four. 
The consent forms describe exome and/ or genome sequencing with varying levels of detail. 
The most complete presentation (study #9) defines sequencing and addresses both the low 
likelihood of identifying diagnostic findings and the potential to identify “genetic changes 
related to other current or future health conditions.” It describes important limitations of 
WES/WGS in this way: “Exome and genome sequencing do not identify all genetic 
alterations or disease risk. Therefore, there may be genetic alterations that will not be 
identified or reported. It is possible that this study will be unable to identify the cause of 
your or your family member’s condition or other health problems…. Failure to identify a 
result will not guarantee that you do not have an alteration in a gene/s or a risk of developing 
disease in the future.” All nine consent forms describe “clinical” purposes of the study; 
“psychosocial” purposes are described in seven, “communication” in five, and “scientific” in 
four. Figure 1 presents the frequency and examples of each study purpose.
1. WHAT CATEGORIES OF RESULTS DO THESE STUDIES PROPOSE TO 
RETURN TO PARTICIPANTS?—The studies differ in the types of genomic results they 
propose to return. All return germline results; three also return somatic (tumor) results. A 
common approach is to list different categories of results that may be returned (or not), 
sometimes with illustrations for each category. For example, study #1 describes “four types 
of genetic information that could be examined at your request: (1) How rapidly a person’s 
body breaks down certain medications and if a person may have a bad response to certain 
medications (2) Whether a person is likely to suffer from a serious medical condition that 
their doctors may be able to prevent such as cancer or sudden cardiac arrest (3) Whether a 
person is likely to suffer from a serious medical condition that cannot be prevented, based 
on current knowledge, such as dementia or Alzheimer’s disease and (4) Whether a person 
carries a gene that doesn’t cause any problems for them, but could lead to problems for their 
children or grandchildren.”
Primary Diagnostic Results vs. Incidental Findings
Given debate over return of primary diagnostic results and incidental findings from clinical 
sequencing, we investigated the terms used to define or distinguish result types. We found 
that three studies distinguish primary diagnostic results from incidental findings, defined in 
one form as “unrelated to the primary diagnosis” (#9); one of these studies defines 
diagnostic information as positive, negative, or uncertain, and incidental information as 
medically actionable or not (#6). A fourth study (#1) recruits individuals who have had 
genetic testing in other studies and offers WES to “better understand the impact of return of 
incidental genetic test results to research participants like yourself.” Three other studies use 
similar words such as “unexpected,” “extra,” and “other.” Another seems to imply this idea: 
“We are likely to find changes in all kinds of genes, not just the genes that are related to the 
health condition that was looked at in the original study” (#7). Two studies do not make the 
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distinction. One (#8) provides examples of potentially clinically relevant results that can be 
returned, including those related and unrelated to the primary disease. The other (#3) enrolls 
“medically-educated staff” and provides little detail about what types of health-related 
results might be returned.
Categories of Results
We identified eight categories of results described in these consent forms: related to health 
and (1) preventable/treatable, (2) not preventable/treatable, or (3) not clear if preventable/
treatable, (4) pharmacogenomics, (5) carrier status; and more generally, (6) nonmedical 
traits, (7) negative results, and (8) uncertain results. The number of results categories ranged 
from one to eight per study, reflecting considerable diversity in study design and population. 
Table 2 shows studies offering each results category, with examples. We also found 
variation in how consent forms address CLIA-certification of results. Four forms state that 
only results from a CLIA-certified laboratory will be returned; two say that some results will 
be from a CLIA-certified lab, but others will not; one is unclear about whether results will 
be from a CLIA-certified lab; one states results will not be from a CLIA-certified lab; and 
one does not address the issue.
2. TO WHAT EXTENT ARE PARTICIPANT PREFERENCES TAKEN INTO 
ACCOUNT IN DETERMINING WHETHER TO RETURN RESULTS?—We used four 
codes to identify whether and on what basis each type of result is returned: (1) the result will 
be returned, (2) participant preferences determine whether the result will be returned, (3) the 
result will not be returned, and (4) return of this type of result is not addressed. Figure 2 
describes the variability we found in categories of results mentioned and the studies’ plans 
for returning results, including the role of participant preferences.
As noted, not all studies mention all types of results and there is variability in the role of 
participant preferences. In two studies (#1, 3), participant preferences determine what is 
returned in all categories. A third study (#7) follows suit, except for “non-medical traits” 
and “negative” and “uncertain” results, which are not returned. In contrast, participant 
preferences play no role in one study (#2). Another study (#4) only mentions results that are 
“related to health and preventable/treatable,” and return depends solely on whether they are 
related to a primary diagnosis. Studies #6, #8, and #9 also return results “related to health 
and preventable/treatable” regardless of participant preferences; however, modes of return 
for other identified categories vary.
Two studies introduce additional complexity about the role of participant preferences. Study 
#5 mentions five types of results, with clear return policy for “carrier status” and “uncertain” 
results, but mixed information regarding return of non-diagnostic information that 
investigators judge to be urgently medically actionable (i.e., “[W]e may tell you and your 
doctor information about this alteration even if you have not previously given us your 
permission to do so.”) Conversely, investigators may decide not to return certain results that 
participants have requested: study #9’s consent form states “receiving results of incidental 
findings without immediate medical impact is voluntary,” yet also lists types of findings that 
the study “may not release.”
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Figure 2 illustrates three observations about return of results. First, for results “related to 
health and preventable/treatable,” returning without consulting participants about their 
preferences is common (6/8 studies). This may be because these studies are seeking 
diagnostic results for affected individuals whose preferences for results are reflected in their 
consent to participate in the study. In study #4, for example, “preventable/treatable” 
diagnostic results are returned without consulting participants, whereas “preventable/
treatable” incidental findings are returned only according to participant preferences. In 
contrast, in two studies (#1, 7), participant preferences govern return of all “preventable/
treatable” results.
The second finding is that more varied approaches to the role of participant preferences are 
evident for categories other than “related to health and preventable/treatable.” This includes 
results “related to health but not preventable/treatable” (e.g., Alzheimer’s or 
neurodegenerative conditions); when “preventable/treatable” is unclear (vague statements 
about learning disease risk with no additional information); and results related to 
pharmacogenomics (depending in part on whether these are related to the primary 
diagnosis). Return of “carrier status,” in contrast, is typically offered only per participant 
preferences (6/7 studies).
Third, some studies explicitly state that they will not return results concerning “non-medical 
traits,” “negative,” and “uncertain” findings. “Uncertain” findings show the greatest 
variation: they will not be returned in three studies (#2, 5, 7); will be returned in one (#6), 
which includes “uncertain” results as one of three diagnostic possibilities; and they are 
returned based on participant preferences in two (#3, 9).
3. HOW ARE POTENTIAL BENEFITS AND RISKS OF PARTICIPATING IN THE 
STUDY DESCRIBED?—Table 3 summarizes how studies describe potential benefits and 
risks of participation. Seven potential benefits are listed on two or more forms; six “other” 
benefits are listed on one form each. Seven studies mention benefit to society (i.e., creation 
of generalizable knowledge); one mentions this as the only benefit. Twelve possible risks of 
harm are listed on two or more forms; six “other” risks are mentioned on one form each. All 
but one of the forms mention both genetic discrimination and loss of privacy as risks of 
participation.
4. HOW ARE PRIVACY, PLACEMENT OF RESULTS INTO THE MEDICAL 
RECORD, RISK OF RE-IDENTIFICATION, AND DATA-SHARING ADDRESSED?
—The volume of information generated by sequencing and the heightened potential for re-
identification create special challenges for privacy and confidentiality.11
Privacy
As shown in Table 3, all but one of the forms mention risks of genetic discrimination and 
loss of privacy. Most reference potential discrimination by insurers and employers, despite 
the partial protection offered by the federal Genetic Information Nondiscrimination Act 
(GINA), which addresses employment and health insurance but does not address other forms 
of insurance such as disability and life insurance. In addition, five forms refer directly or 
indirectly (through mention of “protected health information”) to the protections afforded by 
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HIPAA. No forms refer to additional privacy protections afforded by law. Five forms note 
that the investigators have applied for or obtained a Certificate of Confidentiality.
Information in the Medical Record
Eight forms address placing genetic information in the participant’s medical record. Five 
CSER studies state that results will be placed in the medical record, while the sixth leaves 
the choice to participants. Among the five, there is variation. One states, “all of your reports 
will be placed in your medical record” (#2), while others are selective about the kind of 
information; for example, one (#9) includes “Only validated results that are directly relevant 
to your care at [Institution]” and excludes “Other incidental findings identified solely for the 
purpose of this research study, including results for adult-onset disease and carrier states.” 
Of the three RoR studies, one has an optional plan, one does not address the issue, and one 
(#3) states, “No genetic test results will be put into your medical record as part of this 
study,” yet cautions “if you share these results with a health care provider, the result may be 
included in that providers [sic] record.”
Risk of Re-identification
Four forms explicitly address potential re-identification as a risk of participation. One states, 
“… in the future, people may develop ways to allow someone to link your genetic or 
medical information in these databases back to you” (#2).
Data-Sharing
Seven consent forms address storage and the use of data in other studies. Four of these 
present this as part of the agreement to participate, and three have separate permissions.
Discussion
This analysis of consent forms from the CSER-RoR projects illustrates how investigators are 
grappling with consent-related challenges inherent in new sequencing technologies. These 
challenges include providing clear descriptions of the kinds of expected findings, which 
findings may be returned, the role of participant preferences, and whether results will be 
placed in the medical record. At this early stage in the use of sequencing, there is 
considerable heterogeneity in the responses to these challenges. Though NHGRI provides 
helpful guidance on informed consent for genomic research generally,12 exploration of 
multiple models for consent to clinical sequencing is clearly under way.
All of these studies offer to return at least some findings to participants. However, the 
diversity regarding the types of information that may be returned and the role of participant 
preferences is notable. No category of result is consistently returned in all studies and 
several categories are mentioned in just a few studies. Moreover, the degree to which return 
of results depends on participant preferences varies significantly, ranging from studies that 
determine in advance what will be returned to studies that return only the categories of 
results requested by participants. In one study (#2), no category of potential finding was 
governed by participant preference, while in another study (#1), all categories were. A wide 
range of approaches to return of results in sequencing research was documented in a 2011 
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study,13 and it is striking to see that there remains so little convergence of approaches, as 
sequencing is rapidly evolving.14 On the other hand, we caution that this lack of 
convergence may be less a sign of disagreement over “best” approaches than a reflection of 
the diversity of study designs exploring sequencing.
Indeed, these studies may shed light on the controversial question of whether some findings 
should be returned regardless of participant preferences.15 This question has been 
intensively debated since ACMG’s 2013 recommendation that whenever clinical sequencing 
is performed, a “minimum list” of 56 extra genes should be analyzed for incidental findings 
that are likely to be medically actionable, with no patient option to decline that additional 
analysis.16 Five of the studies we analyzed are exploring return of specific categories of 
medically actionable results regardless of participant preferences, although these results are 
generally diagnostic findings, in contrast to the incidental findings addressed by the ACMG 
recommendations. Approaches to the return of medically actionable incidental findings 
unrelated to diagnosis are more mixed: some studies return them without consulting 
participant preferences, whereas others only return them based on participant preferences. 
Some studies in our sample are returning results regardless of participant preferences even 
when not in the medically actionable, “preventable/treatable” category. This wide range of 
approaches to the role of participant preferences should yield data to inform best practices. 
However, the diversity of approaches suggests the need to address underlying societal norms 
and professional values that motivate offers of different types of results with varying 
attention to participant/patient preferences in both research and clinical settings. As noted 
above, ACMG has now modified its approach to incidental findings in clinical sequencing, 
recommending that patients be allowed to opt out of the analysis for medically actionable 
incidental findings.17
Our analysis revealed considerable variation in potential benefits and risks described (Table 
3). In addition, we found varying approaches to data-sharing and the potential for re-
identification of genomic results. We also found a range of approaches to whether genomic 
information would be placed in the participant’s medical record, which information, and the 
role of participant preferences. This points to the challenging questions of how to integrate 
genomics into the medical record, specifically the electronic health record, and whether 
placing incidental findings in the medical record raises somewhat different issues than 
recording diagnostic results and may require separate consent.18
Given the range of approaches we found across a spectrum of results categories, our coding 
tasks were complex and challenging. The coding categories emerged from reading all nine 
consent forms. Coding became difficult when a consent form addressed multiple categories 
of results, took different approaches to the role of participant preferences in returning 
different categories of results, or presented unclear or conflicting information about 
categories or preferences. These features made it challenging to identify how different 
categories of results were handled in some studies. Indeed, two studies have language in 
different sections of the consent forms that suggests circumstances in which the investigator 
can override participant preferences, as noted above. These provisions may have been 
motivated by investigators’ desires to preserve their discretion with regard to decisions 
about return, given uncertainties at the inception of projects about what types of results 
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might be encountered or what policies might be formulated by return-of-results committees. 
Whatever their origin, conflicting messages are likely to be at least as difficult for research 
participants to interpret as they were for our team. Complicating this further, no form 
reaches the often-recommended eighth-grade level of reading ease,19 though none exceeds 
the level expected of a high-school graduate.
This analysis has limitations. We assessed consent forms from a small number of studies, 
designed early in the process of clinical translation of WES and WGS. Forms from three 
additional CSER studies funded subsequent to the completion of our data analysis were not 
analyzed here, and a number of other research groups are now engaged in or planning 
sequencing studies. Indeed, several studies included here have since modified or added 
consent forms that might alter our initial coding results. Hence, our results represent a 
snapshot in time, reflecting evolving approaches. Our analysis focuses exclusively on the 
content of consent forms, which is only a part of the consent process. Thus, the forms may 
not fully reflect more detailed procedures specified in study protocols, to which we did not 
have access. We did not analyze supplemental oral communication or how these forms are 
used in practice, though in some cases our familiarity with the studies in question allowed us 
to clarify uncertain study design information. Some investigators in the studies whose forms 
are analyzed here have indicated that their study uses instruments beyond the consent form 
(such as an educational DVD or a separate questionnaire) to communicate further with 
participants about specific categories of results and solicit preferences; those additional 
instruments were not part of our coding. Lastly, coder misclassification may have occurred, 
though all forms were coded by multiple individuals with disagreements resolved, results 
discussed by our broader author group, and when questions arose, coding decisions checked 
against the original consent forms.
Notwithstanding these limitations, our findings may be helpful in suggesting ways in which 
consent forms for WES/WGS studies can be improved, and potentially consent forms for 
clinical sequencing as well. Based on our review, we offer the following recommendations: 
(1) define WES/WGS and address its limitations; (2) describe the processes and challenges 
of expert review that determine the results to be returned, and the role of CLIA certification; 
(3) describe possible results related to diagnostic or incidental findings (if that distinction is 
appropriate for the context), state the likelihood of producing such results, and indicate 
whether they are related to conditions that are preventable/treatable; (4) specify the 
meanings of positive, negative, and uncertain results; (5) describe the role of patient or 
participant preferences in return of results; (6) specify the potential benefits and risks of 
participation (including benefit to society, when sequencing is performed in the research 
context); and (7) consider the many facets of privacy, placing findings in the medical record, 
de-identification, data-sharing, and risk of re-identification. These recommendations, based 
on comparing and analyzing the consent forms in this study, can serve as a checklist to help 
identify gaps and resolve ambiguities in consent forms for sequencing. Our 
recommendations go beyond the general guidance offered by NHGRI on seeking consent to 
genomic research20 by focusing on key elements needed in consent to sequencing, such as 
clarity about the limitations of WES/WGS, a description of the processes that will be used to 
determine which results to return, and the meaning of positive, negative, and uncertain 
results.
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Selecting among approaches to return of results and incidental findings will depend on a 
variety of factors, including research population and study aims. It will also depend on 
normative positions concerning the entitlement of participants to determine which results 
they will receive, and empirical findings regarding the impact of individual genomic results 
and incidental findings on participants’ psychological well-being, health-related practices, 
and medical care. The wide variation in practices revealed by our analysis highlights the 
diverse strategies currently being used to address the practical challenges of genomic 
sequencing of study participants and patients. As researchers and clinicians gain experience 
with new forms of genomic analysis, it will be important to develop evidence-based and 
normatively sound points of consensus on best practices for informed consent and return of 
both diagnostic results and incidental findings in exome and genome sequencing.
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Figure 2. Study ID by Categories of Results and Mode of Return When Offered
*In three instances, the mode of return required two codes assigned to one “cell’.” To 
illustrate, in study #5, the “preventable/treatable” cell for study #5 is assigned both “results 
will be returned” and “participant preferences will determine whether or not the result will 
be returned.” In this case, “result will be returned” refers to results related to the main 
diagnosis that are “preventable/treatable,” while the latter refers to return of incidental 
findings that are also “preventable/treatable.”
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1Override. This describes instances where the consent form states that the participant has the 
option to choose the results returned, but then later states that the study may override the 
participant’s decision with respect to certain kinds of results. Study #5 notes that 
investigators may override participant preferences regarding non-diagnostic information 
when information is considered urgently medically actionable. Studies #5 and #9 also 
describe an override in the opposite direction, in which participants may choose certain 
types of non-medically actionable incidental findings yet investigators may decide not to 
release them.
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Table 1
Study and Consent Form Characteristics
Study Characteristics Number of Studies
Funding source
    NHGRI & NCI Clinical Sequencing Exploratory Research U01 6
    NHGRI R01 3
Population enrolled
    Adults only 4
    Children only 1
    Adults and children 2
    Adults and other family members 1
    Children and other family members 1
Disease or Condition1
    Cancer 4
    Cardiovascular 3
    Intellectual disability/neurological 3
    Unaffected 2
Type of sequencing
    Whole-exome 4
    Whole-genome 1
    Both whole-exome and whole-genome 4
Focus of sequencing
    Germline only 6
    Both germline and somatic 3
Comparison group
    Yes 5
    No 4
Consent Form Characteristics Across Studies
Word count
    Mean 4588
    Range 2917–5757
Reading level of consent form (Flesch-Kincaid Grade Level)
    Median grade level 10.8
    Range 9.4–11.7
1
Some studies focused on more than one disease condition.
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Table 2
Examples of Categories of Results and Number of Studies That Mention the Category
Category Example
Preventable/Treatable (8/9)
“These will include results related to your primary diagnosis and incidental findings that require an 
immediate medical action (IMA).These are findings with an immediate impact on your health or 
healthcare in childhood…” (#9)
“There are 4 types of genetic information that could be examined [at the participant’s request]. One of 
them is whether a person is likely to suffer from a serious medical condition that their doctors may be 
able to prevent such as cancer or sudden cardiac arrest.” (#1)
Not Preventable/ Treatable (5/9)
One type of finding is.. .”Whether a person is likely to suffer from a serious medical condition that 
cannot be prevented, based on current knowledge such as dementia or Alzheimer’s disease…” (#1)
“You will also be asked if you want to learn non-medically actionable incidental information. Before 
you decide, we will discuss the different categories (bins) of non-medically actionable incidental 
information that you could learn.” (#6)
“Results related to certain untreatable adult onset disorders, such as dementia or other 
neurodegenerative disease.” (#9)
Not Clear if Preventable/ 
Treatable (4/9)
“Disease Risk: Gene changes that increase your risk of getting a disease or health condition.. .”(#7)
“Results that cause a difference in response to medication or a minor increased risk for common adult 
onset diseases such as heart disease or Alzheimer’s disease…” (#9)
“We plan to only return results to you if we feel that there is strong evidence that they may help you 
manage risk of disease, predict future disease, tell you that you carry a recessive gene that could impact 
a future child or help predict your response to a drug.” (#2)
Pharmacogenomics (6/9)
“Genes from your normal blood cells may contain an alteration that affects the way your body handles a 
cancer medication. This information might mean that you need a higher or lower dose than usual for 
that cancer medication.” (#5)
“Gene changes that affect how your body responds to certain medications…” (#7)
“Results that cause a difference in response to medication…” (#9)
Carrier Status (7/9)
“.. .an alteration for a condition (other than cancer) that you might pass on to your child. This is possible 
even if you do not have the condition yourself. For example, tests might show that you carry a gene 
alteration for cystic fibrosis that could be passed on to your child.” (#5)
“If a child has one of these kinds of mutations, he or she probably inherited it from a parent. Therefore 
the parents might want to be screened to see if there is a risk of having a child who has a genetic 
disorder. However, some people do not want to know this kind of information. Please initial below 
whether you would like this type of genetic information to be included in your child’s exome 
sequencing report.” (#8)
Non-medical Traits (3/9)
“it will not include other information about personal genetic traits such as eye or hair color…”(#2)
“Results that do not have associated health problems, such as baldness…” (#9)
Negative (2/9)
“…no potentially causative variant has been identified that explains your personal and/or family history 
in the subset of genes that was studied…” (#6)
“Results that indicate that you do NOT have a disease-causing change in a gene…” (#7)
Uncertain (6/9)
“Gene alterations may be found that do not have clear implications for your health…” (#5)
“A variant has been identified in a gene associated with a genetic disorder that may explain your 
personal and/or family history but the clinical meaning of that variant is not known for certain.” (#6)
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Table 3
Potential Benefits and Risks of Participation Identified in 9 Consent Forms
Potential Benefits:
Benefit to society 7
Information on risk of another disease [other than primary condition] 7
Information on cause of condition 4
Information on reaction to medications 4
Information for reproductive decision-making 4
Identify treatment for your condition 3
Information on prognosis 2
Other (listed on only one form each) 6
Potential Risks:
Blood draw risks 9
Emotional & psychological distress for self and family 9
Genetic discrimination 8
Loss of privacy 8
Unknown risks 7
Tension among family members 5
Potential for re-identification 4
Emotional & psychological distress from discussing personal things 3
Potential for inaccurate information 3
Emotional & psychological distress from uncertainty 2
Financial costs downstream 2
Other (listed on only one form each) 6
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